ストックスクリーナーアプリを入手
0.00
100.00%
-14.49
前日終値:
$14.49
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$4.55B
収益：
$634.21M
当期純損益:
$-27.11M
株価収益率:
0.00
EPS:
-0.0885
ネットキャッシュフロー:
$29.85M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$14.50
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
0.00 | 4.55B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-29 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-12-17 | 開始されました | Citigroup | Buy |
| 2025-09-18 | アップグレード | Needham | Hold → Buy |
| 2025-07-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
FOLD Q4 2025 Earnings: EPS Misses Consensus by 94.35% as Company Reports Near-Breakeven ResultsPost-Earnings Drift - Vinanet
Asia Pacific Imiglucerase Market 2026-2033: Growth Overview, - openPR.com
Goldman Sachs (FOLD) filing shows no beneficial stake in Amicus stock - Stock Titan
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth - MarketBeat
FOLD Q4 2025 Earnings: EPS Misses Consensus by 94% as Profit Narrows to $0.005Buyback Announcement Report - Vinanet
Amicus Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Amicus Therapeutics Q4 2025 Earnings: EPS Misses Estimates by a Wide Margin Despite Narrow LossNet Income Trends - dars.gov.et
Amicus Therapeutics Reports 2025 Financial Results, Merger With BioMarin, and Key Pipeline Updates - Minichart
BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms - Stock Titan
Our Origin Story - BioMarin Pharmaceutical
Amicus Therapeutics Inc (FOLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amicus Therapeutics Inc (FOLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amicus Therapeutics (FOLD) Holds Steady at $14.49 Amid Consolidation PhaseSpring Pattern - dars.gov.et
Amicus Therapeutics Inc (FOLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amicus Therapeutics Q2 2025 Earnings Preview - MSN
Amicus Therapeutics Stock (US03152W1099): valuation picture in focus for biotech name FOLD - ad-hoc-news.de
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech - BioSpace
BioMarin Pharmaceutical's Revenue Guidance Boost Reflects Pipeline Progress and Acquisition GrowthPost-Announcement Reaction - po-news-eg.net
Amicus Therapeutics Holds Steady at $14.49 as Key Levels Define Trading RangeAAII Bullish - DonanımHaber
Amicus Therapeutics (FOLD) Holds Steady at $14.49 as Traders Eye Key Resistance LevelFloat Adjusted Cap - dars.gov.et
John Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 moves - MSN
Amicus Therapeutics (FOLD) Holds Steady Near Support as Biotech Sector Waits for CatalystEarnings Breakout Stocks - dars.gov.et
Amicus Therapeutics stock (US03152W1099): analysts see limited upside after strong run - AD HOC NEWS
Are Amicus Therapeutics (FOLD) and Autoliv (ALV) Overlooked Opportunities - Kavout
Paulson & Co. Acquires Amicus Therapeutics (FOLD) and Exits Solstice Advanced Materials (SOLS) - GuruFocus
Barclays holds 17.8M Amicus shares (NASDAQ: FOLD), 5.65% stake - Stock Titan
Amicus Therapeutics stock (US03152W1099): Biotech focused on rare diseases - AD HOC NEWS
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer - Fierce Pharma
Goldman Sachs (FOLD) discloses 16.78M shares, 5.3% ownership (Schedule 13G) - Stock Titan
Fabry Disease Treatment Market to Reach USD 3,530.5 Million - openPR.com
BioMarin Q1 earnings miss, sales beat, '26 revenue guidance raised - MSN
Amicus Therapeutics (Delisted) | SCHEDULE 13G: Others - Moomoo
UBS Group-affiliated funds hold 17.14M shares in Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
[15-12G] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Which Is a Better Investment, AnaptysBio, Inc. or Amicus Therapeutics, Inc. Stock? - AAII
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition (NASDAQ:BMRN) - Seeking Alpha
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
MSN Money - MSN
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
1.86%
大文字化:
|
ボリューム (24 時間):